Spruce Biosciences, Inc. (SPRB)
| Market Cap | 505.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.35M |
| Shares Out | 22.26M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $22.00 |
| Previous Close | $21.72 |
| Change ($) | 0.28 |
| Change (%) | 1.29% |
| Day's Open | 21.75 |
| Day's Range | 21.01 - 22.42 |
| Day's Volume | 15,385 |
| 52-Week Range | 15.38 - 32.42 |
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular wa...
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week
Shares of Spruce Biosciences Inc. rallied in their public debut, as they opened 21% above the initial public offering price. The stock's first trade was at $18.14 at 11:37 a.m.
Spruce Biosciences Inc. said Friday that its initial public offering, which was upsized by 20%, priced at $15 a share, as the California-based biopharmaceutical company developing treatments f...
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Announces Pricing of Upsized Initial Public Offering
About SPRB
Spruce Biosciences, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize com... [Read more...]
| Industry Biotechnology | IPO Date Oct 9, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol SPRB |
Analyst Forecasts
According to 4 analysts, the average rating for SPRB stock is "Buy." The 12-month stock price forecast is 33.75, which is an increase of 53.41% from the latest price.